Impel Pharmaceuticals to preset real-world data for Trudhesa

Impel Pharmaceuticals announced it will present new real-world data adding to the growing body of evidence supporting Trudhesa nasal spray as an effective acute therapy for migraine management. The findings will be featured in two poster presentations during the 65th Annual Scientific Meeting of the American Headache Society, taking place June 15-18, 2023, in Austin, Texas. Preliminary real-world findings from an assessment of medical and pharmacy claims data for patients with migraine who were treated with Trudhesa in the United States provide new evidence suggesting that concomitant preventive and acute medication use generally decreases in patients taking Trudhesa between the 12-month baseline and 90-day follow-up period. Importantly, an increase in antinausea medications was not observed following Trudhesa use, whereas these medications are commonly used with DHE administered intravenously. “DHE has an established safety and efficacy profile, often providing long-lasting relief for even the toughest of migraine attacks. However, until Trudhesa, nasal delivery options couldn’t reach the upper nasal space, where DHE can be rapidly absorbed,” said Zubair Ahmed, M.D., a headache specialist and neurologist at the Cleveland Clinic. “Trudhesa has been an important addition to migraine care as it provides patients with the reliable relief of DHE in a new and easy-to-use delivery technology that can provide relief in as early as 15 minutes and, importantly, be administered at any point during an attack. This real-world evidence indicates that patients who respond to Trudhesa will likely continue to respond long-term, providing an additional benefit of potentially reducing the need for using daily oral concomitant preventative and acute medications.” A second poster on real-world demographic and clinical characteristics, as well as baseline comorbidities among patients with migraine who were treated with Trudhesa, found that most patients were females between the ages of 36 and 45 years, and had comorbidities that include headache syndromes other than migraine, other neurological conditions, other pain disorders, sleep disorders, gastrointestinal (GI) disorders, and psychiatric disorders.